Medical Devices; Radiology Devices; Classification of the Phase-Changing Fiducial Marker for Radiation Therapy
Published Date: 7/29/2026
Rule
Summary
The Food and Drug Administration (FDA) is classifying the phase-changing fiducial marker for radiation therapy into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the phase-changing fiducial marker for radiation therapy. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 1 costs, 1 mixed.
Required clinical, lab, and labeling tests
To be in this Class II category, manufacturers must meet special controls that include clinical performance data (e.g., marker migration, visibility, tumor response interference, adverse events), animal performance data (toxicity and migration), non-clinical performance data (physical form maintenance, imaging visibility, interference with dose), biocompatibility, sterility and shelf-life testing, usability testing, and specified labeling content (materials/composition, adverse events summary, injection procedure, and shelf life).
Device moved to Class II
The FDA has classified the phase-changing fiducial marker for radiation therapy as Class II (special controls). This final order is effective July 29, 2026, and the classification was applicable on December 23, 2022. The FDA says this classification will provide reasonable assurance of safety and effectiveness and may enhance patient access by reducing regulatory burdens.
Device subject to 510(k) requirement
The phase-changing fiducial marker is subject to premarket notification under section 510(k) of the Federal Food, Drug, and Cosmetic Act and is not exempt under section 510(m). Manufacturers must therefore submit a 510(k) to market this Class II device.
Classification enables future 510(k) predicates
Because FDA classified this device via the De Novo process, the phase-changing fiducial marker can serve as a predicate device for future 510(k) submissions, allowing other sponsors to use the less-burdensome 510(k) pathway instead of De Novo or PMA for substantially equivalent devices.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-15285, Product-Specific Guidances; Revised Draft Guidances for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of additional revised draft product-specific guidances. The draft guidances provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry entitled "Bioequivalence Recommendations for Specific Products" that explained the process that would be used to make product-specific guidances available to the public on FDA's website. The draft guidances identified in this notice were developed using the process described in that guidance.
2026-15187, Cancer Clinical Trial Eligibility Criteria: Laboratory Values; Guidance for Industry, Institutional Review Boards, and Clinical Investigators; Availability
The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a final guidance for industry, institutional review boards (IRBs), and clinical investigators entitled "Cancer Clinical Trial Eligibility Criteria: Laboratory Values." This guidance is one in a series of guidances that provide recommendations regarding eligibility criteria for clinical trials of investigational drugs regulated by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation Research (CBER) for the treatment of cancer. Specifically, this guidance includes recommendations for selecting appropriate laboratory values as trial eligibility criteria to avoid unjustified exclusions of trial participants. This guidance finalizes the draft guidance of the same title issued on April 26, 2024.
2026-15186, Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications; Guidance for Industry, Institutional Review Boards, and Clinical Investigators; Availability
The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a final guidance for industry, institutional review boards (IRBs), and clinical investigators entitled "Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications." This guidance is one in a series of guidances that provide recommendations regarding eligibility criteria for clinical trials of investigational drugs regulated by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation Research (CBER) for the treatment of cancer. Specifically, this draft guidance includes recommendations regarding the appropriate use of washout periods and concomitant medication exclusions. This guidance finalizes the draft guidance of the same title issued on April 26, 2024.
2026-15147, Fee Rate for Using a Priority Review Voucher in Fiscal Year 2026; Correction
The FDA fixed some details about the fee for using a Priority Review Voucher in 2026. If you're submitting a drug application using one of these special vouchers, you now have to pay the fee right when you submit your application. This change affects companies working on rare pediatric diseases, tropical diseases, or medical countermeasures, and it kicks in starting February 3, 2026.
Previous / Next Documents
Previous: 2026-15300, Safety Zone; Lake Ontario, Olcott, NY
On August 8, 2026, from 8:45 p.m. to 10:15 p.m., the Coast Guard is setting up a temporary safety zone on Lake Ontario near Olcott, NY, to keep people and boats safe during a fireworks show. No one can enter the zone unless the Coast Guard says it’s okay. This quick action helps protect everyone without any extra costs or delays.
Next: 2026-15308, Airworthiness Directives; Airbus SAS Airplanes
The FAA is superseding Airworthiness Directive (AD) 2025-16- 12, which applied to all Airbus SAS Model A319-151N, -153N, -171N, and -173N airplanes; Model A320-251N, -252N, -253N, -271N, -272N, and -273N airplanes; and Model A321-251N, -252N, -253N, -271N, -272N, -251NX, - 252NX, -253NX, -271NX, -272NX, -253NY, and -271NY airplanes. AD 2025- 16-12 required revising the existing airplane flight manual (AFM) and the existing FAA-approved minimum equipment list (MEL), allowed replacement of each affected high-pressure bleed valve (HPV) as an optional terminating action, and prohibited the installation of affected parts. Since the FAA issued AD 2025-16-12, the FAA has determined that repetitive replacement of the HPV clips is necessary to address the unsafe condition. This AD continues to require the actions in AD 2025-16-12 and requires repetitive replacement of each affected HPV clip. The FAA is issuing this AD to address the unsafe condition on these products.